| Name | Title | Contact Details |
|---|
The Pursuant Group is a Plano, TX-based company in the Business Services sector.
Tomhaven Group, The is a Baltimore, MD-based company in the Business Services sector.
Predict, Prevent and Protect The workplace is changing, however, the tools to manage worker risks have not evolved. Increasing financial, premium, and reputation costs and the challenge of ensuring compliance while improving workplace culture, require new tools for the new normal. There are increased risks through distributed teams, the gig economy, and return-to-work compliance issues. If litigation ensues, employers lose 72% of lawsuits with settlements averaging $1.6 million. How can a company ensure consistent compliance and reduced claims while improving workplace culture? RiskKarma serves as a holistic compliance and culture platform that utilizes a two-pronged approach through an analysis of employer practices and worker actions. RiskKarma provides a comprehensive view of an employers risk exposure to predict, prevent and protect against crime, fraud, and claims. Our platform harnesses the power of AI to identify key indicators of emerging risk so that leadership can take steps to prevent and mitigate worker-related events and their costs. Our modular solution affords the tools to; make data-driven decisions, automate compliance, meet ESG and DEI initiatives, and standardize governance. Through compliance gamification, portable risk profiles, and skills strength validation, workers know where they stand and have a vested interest in maintaining a risk-free and non-discriminatory environment. For insurers, RiskKarma.io serves as a risk Prevention and Mitigation solution that assists in reducing both claims and LAE costs. Through real-time intelligent risk metrics, insurers have insights into an insureds unique risk profile and the impact of current loss control measures.
Skye Bioscience Inc. is a clinical-stage biotechnology company based in San Diego, California. The company focuses on developing innovative therapeutics for metabolic diseases, particularly obesity, by modulating the endocannabinoid system. Skye Bioscience is advancing its lead product, Nimacimab, a monoclonal antibody that targets peripheral CB1 receptors. This treatment aims to provide effective weight loss solutions while minimizing neuropsychiatric side effects associated with previous therapies. Nimacimab is currently in a Phase 2 trial, evaluating its efficacy in weight loss and metabolic health. The company is also exploring combination therapies to enhance treatment outcomes. Skye Bioscience positions Nimacimab as a potential alternative to existing GLP-1-based therapies, targeting patients who need sustainable weight loss with improved safety profiles. The obesity drug market presents significant opportunities, and Skye is actively participating in clinical trials and industry conferences to advance its mission in metabolic health.
Marshall-teichert Group is a Hopkins, MN-based company in the Business Services sector.